ASCO China Perspective | Professor Kun Wang: Seven-Year KEYNOTE-522 Data Reinforce Curative Potential for High-Risk Early TNBC

ASCO China Perspective | Professor Kun Wang: Seven-Year KEYNOTE-522 Data Reinforce Curative Potential for High-Risk Early TNBC

In the era of chemotherapy alone, patients with high-risk early-stage triple-negative breast cancer (TNBC)—particularly those with node-positive disease or more advanced tumors—continued to face a substantial risk of recurrence after surgery, making cure an ambitious goal for many. Over the past few years, however, immune checkpoint inhibitors (ICIs) and antibody-drug conjugates (ADCs) have rapidly moved from the metastatic setting into early-stage treatment, bringing new hope for long-term survival and potential cure.
2026 Lingnan Breast Cancer Forum | Ciqiu Yang: Precision Decision-Making for Breast-Conserving Surgery and Axillary Preservation After Neoadjuvant Therapy

2026 Lingnan Breast Cancer Forum | Ciqiu Yang: Precision Decision-Making for Breast-Conserving Surgery and Axillary Preservation After Neoadjuvant Therapy

Neoadjuvant therapy has created new opportunities for breast-conserving surgery and axillary preservation in patients with breast cancer. However, accurately defining the extent of surgery after neoadjuvant treatment and determining the optimal management of axillary lymph nodes remain among the most important and challenging issues in contemporary breast cancer care.
2026 Lingnan Breast Cancer Forum | Professor Kun Wang: Advancing Integrated Prevention and Care Across the Entire Breast Cancer Journey

2026 Lingnan Breast Cancer Forum | Professor Kun Wang: Advancing Integrated Prevention and Care Across the Entire Breast Cancer Journey

The 2026 Lingnan Breast Cancer Forum was recently held in Guangzhou, bringing together breast cancer specialists from across China to discuss the latest advances in prevention, diagnosis, treatment, and survivorship. Centered on the concept of whole-course breast cancer management, the meeting integrated the year's most important international breakthroughs with a comprehensive scientific program covering early detection, precision diagnosis, individualized treatment, innovative therapies, and postoperative rehabilitation.
2026 Beijing Breast Cancer Forum | Professor Shu Wang: Integrating Innovation and Collaboration to Advance High-Quality Breast Surgery

2026 Beijing Breast Cancer Forum | Professor Shu Wang: Integrating Innovation and Collaboration to Advance High-Quality Breast Surgery

In June, Beijing became a vibrant hub for academic exchange as the 2026 Beijing Breast Cancer Forum and Beijing Breast Reconstruction Forum—hosted by the Beijing Breast Disease Prevention and Treatment Society and organized by the Breast Center of Peking University People's Hospital—was held as a week-long scientific meeting from June 23 to 28, 2026.
2026 Beijing Breast Cancer Forum | Professor Miao Liu: Current Clinical Applications of MRD in Breast Cancer and the Future of Precision Oncology

2026 Beijing Breast Cancer Forum | Professor Miao Liu: Current Clinical Applications of MRD in Breast Cancer and the Future of Precision Oncology

Although advances in diagnosis and treatment have substantially improved outcomes for patients with early-stage breast cancer, several important unmet clinical needs remain. Conventional risk stratification based on clinicopathological characteristics lacks sufficient precision to accurately identify patients at genuine risk of recurrence, resulting in undertreatment of some high-risk patients and overtreatment of others. During neoadjuvant therapy, current assessment methods are also unable to detect treatment response at the molecular level early enough to guide timely therapeutic adjustments.
Pujiang Prostate Cancer Conference | Prof. Guowen Lin: Three Key Assessment Dimensions for Selecting Candidates for Salvage Prostatectomy and New Surgical Strategies for Recurrence After Focal Ablation

Pujiang Prostate Cancer Conference | Prof. Guowen Lin: Three Key Assessment Dimensions for Selecting Candidates for Salvage Prostatectomy and New Surgical Strategies for Recurrence After Focal Ablation

The Pujiang Prostate Cancer Conference was held in Shanghai on June 26–27, 2026. Organized by the Shanghai Anti-Cancer Association and its Genitourinary Oncology Committee, and hosted by Fudan University Shanghai Cancer Center, the meeting focused on major clinical issues including salvage surgery following prostate cancer recurrence and the integration of multiple local treatment modalities.
Pujiang Prostate Cancer Conference | Prof. Yao Zhu: The Clinical Significance of the APCCC Consensus—Bridging Clinical Guidelines and Real-World Practice

Pujiang Prostate Cancer Conference | Prof. Yao Zhu: The Clinical Significance of the APCCC Consensus—Bridging Clinical Guidelines and Real-World Practice

The 2026 Pujiang Prostate Cancer Conference was held in Shanghai on June 26–27, 2026, under the theme "Standardization, Precision, Chinese Innovation, and Global Collaboration." The conference featured in-depth discussions on key topics including early prostate cancer screening and precision diagnosis, optimization of local treatment strategies, innovation in advanced disease management, and the development of comprehensive care throughout the disease course.